CIFoundry
Back to Catalog
Radiology
FDA Cleared

Paige Prostate (Paige Prostate Detect)

Save to shortlist
Paige AI, Inc. (subsidiary of Tempus AI)2017

Last reviewed Nov 11, 2026 against the sources listed on this page · How we review

At a glance

Paige Prostate is the first AI-based digital pathology product to receive FDA De Novo marketing authorization (September 2021), acting as an in vitro diagnostic that flags suspicious foci on…

FDA:
De Novo DEN200080
Epic:
Not on record
Named users:
4 reported by the maker
Published study:
Yes, linked below

Description

Paige Prostate is the first AI-based digital pathology product to receive FDA De Novo marketing authorization (September 2021), acting as an in vitro diagnostic that flags suspicious foci on digitized prostate needle-biopsy whole-slide images. In a pivotal study of 16 pathologists and 527 slides it raised average sensitivity from 89.5% to 96.8% and cut false negatives by 70%. It is used as a 'second set of eyes' alongside the FDA-cleared FullFocus digital pathology viewer.

radiologydigital pathologyprostate cancerwhole-slide imagingFDA De Novoin vitro diagnosticcancer detection

Quick answers

Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review

Is Paige Prostate (Paige Prostate Detect) FDA cleared?
The public FDA database has one record that our team matched to Paige Prostate (Paige Prostate Detect). The most recent is De Novo DEN200080 (Paige Prostate), decided Sep 2021. Check that the cleared use matches how you plan to use it.FDA record DEN200080
Is there published research on Paige Prostate (Paige Prostate Detect)?
Yes, this listing links a published study. Check whether the patients and setting in the study look like yours.Read the study

Security & contracting

The maker has not reported these details yet. Ask the vendor directly during evaluation.

Workflow stage
Not reported
Integrations
Not reported
Data inputs
Not reported
Deployment
Not reported
Signs a BAA
Not reported
SOC 2 report
Not reported
HITRUST
Not reported
Evidence type
Not assessed

Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.

Who's using this

4 organizations

Organizations named in public announcements or by the developer. Inclusion is not an endorsement.

Reported by the developer

North Bristol NHS Trust (Southmead Hospital)University Hospitals Coventry and Warwickshire NHS TrustOxford University NHS Foundation TrustYale (clinical study site)

Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.

Get weekly updates for Radiology

Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.

Sources

This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.

Website Research Paper

FDA database records

  • DEN200080 · De Novo · Sep 2021
    Paige Prostate

Matched by our team from the public FDA database; checked Nov 10, 2026.

History (2)Show

Dated events on this listing's public record, newest first.

  1. Sep 13, 2026

    Added to CIFoundry

  2. Sep 21, 2021

    FDA De Novo DEN200080 decision datesource

https://www.paige.ai/contact-us (HQ: 11 Times Square, 37th Floor, New York, NY 10036, USA)

Developer

Paige AI, Inc.

Paige AI, Inc. (subsidiary of Tempus AI)

Evaluating this tool?

Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.

Prepare evaluation packet

Checklist for your role: Admin · Physician · IT · Compliance

Compare similar tools →

Own this tool?

Claim this listing to update its details and connect with your audience.